Guidance, tools, and published evidence to help programs make the case for ASP staffing.
of studies found that more ASP resourcing was associated with reduced antimicrobial use (17 of 21).
Langford BJ, et al. JAC Antimicrob Resist. 2026.cost studies in the scoping review reported lower costs with increased ASP resourcing.
Langford BJ, et al. JAC Antimicrob Resist. 2026.estimated antimicrobial cost savings per additional 0.1 ASP FTE, used in the SPARC calculator.
Langford BJ, et al. JAC Antimicrob Resist. 2026.of hospital ASP studies showed a decrease in antibiotic expenditure after program implementation.
Nathwani D, et al. Antimicrob Resist Infect Control. 2019;8:35.average length-of-stay reduction among studies with a statistically significant change (20.6% shorter stay).
Nathwani D, et al. Antimicrob Resist Infect Control. 2019;8:35.average cost savings per patient in U.S. studies (range $2.50–$2,640). Length of stay was the main driver.
Nathwani D, et al. Antimicrob Resist Infect Control. 2019;8:35.Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Society of Infectious Diseases Pharmacists, and American Society of Health-System Pharmacists. Under review. 2026.
Association of Medical Microbiology and Infectious Disease Canada. Toolkit. 2017.
National Collaborating Centre for Infectious Diseases. CAN-AMS! Webinar. 2025.
Nathwani D, et al. Antimicrob Resist Infect Control. 2019;8:35.
Langford BJ, et al. JAC Antimicrob Resist. 2026.
